PRINCETON, N.J. and CAMBRIDGE, Mass., Oct. 12, 2025 /PRNewswire/ — Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib, an oral […]
PRINCETON, N.J. and CAMBRIDGE, Mass., Oct. 12, 2025 /PRNewswire/ — Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib, an oral […]
